{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:58Z","timestamp":1788391198502,"version":"build-2803163510"},"reference-count":154,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.022","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"895-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Oncology in Pediatric Cancer Surgery"],"prefix":"10.1016","volume":"40","author":[{"given":"William G.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.hoc.2026.05.022_bib1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.022_bib2","unstructured":"Society AC. Cancer Facts & Figures 2023. American Cancer Society. Accessed March 21, 2023, https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdfhttps:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf."},{"issue":"20","key":"10.1016\/j.hoc.2026.05.022_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1056\/NEJMc2201761","article-title":"Current causes of death in children and adolescents in the United States","volume":"386","author":"Goldstick","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.022_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/pbc.24422","article-title":"Children\u2019s Oncology Group\u2019s 2013 blueprint for research: survivorship and outcomes","volume":"60","author":"Armenian","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.022_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children\u2019s oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7696","key":"10.1016\/j.hoc.2026.05.022_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"issue":"6432","key":"10.1016\/j.hoc.2026.05.022_bib7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1126\/science.aaw3535","article-title":"The genomic landscape of pediatric cancers: Implications for diagnosis and treatment","volume":"363","author":"Sweet-Cordero","year":"2019","journal-title":"Science"},{"issue":"7457","key":"10.1016\/j.hoc.2026.05.022_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3349","article-title":"Mutational dynamics between primary and relapse neuroblastomas","volume":"47","author":"Schramm","year":"2015","journal-title":"Nat Genet"},{"issue":"7696","key":"10.1016\/j.hoc.2026.05.022_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","article-title":"A first-generation pediatric cancer dependency map","volume":"53","author":"Dharia","year":"2021","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1078-0432.CCR-11-1921","article-title":"Epigenetic changes in pediatric solid tumors: promising new targets","volume":"18","author":"Lawlor","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"7586","key":"10.1016\/j.hoc.2026.05.022_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature16478","article-title":"Divergent clonal selection dominates medulloblastoma at recurrence","volume":"529","author":"Morrissy","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41416-023-02208-y","article-title":"Genomic ALK alterations in primary and relapsed neuroblastoma","volume":"128","author":"Rosswog","year":"2023","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.022_bib17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/ng.3438","article-title":"TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors","volume":"47","author":"Valentijn","year":"2015","journal-title":"Nat Genet"},{"issue":"141","key":"10.1016\/j.hoc.2026.05.022_bib18","first-page":"51","article-title":"BRAF alterations in primary brain tumors","volume":"26","author":"Maraka","year":"2018","journal-title":"Discov Med"},{"issue":"6689","key":"10.1016\/j.hoc.2026.05.022_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib20","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J Clin Invest"},{"issue":"7384","key":"10.1016\/j.hoc.2026.05.022_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"7697","key":"10.1016\/j.hoc.2026.05.022_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.022_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","article-title":"Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma","volume":"86","author":"Geoerger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.022_bib26","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children\u2019s Oncology Group Study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib27","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2147\/DDDT.S147384","article-title":"Entrectinib and other ALK\/TRK inhibitors for the treatment of neuroblastoma","volume":"12","author":"Pacenta","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.022_bib28","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","article-title":"Activity of Crizotinib in Patients with ALK-Aberrant Relapsed\/Refractory Neuroblastoma: A Children\u2019s Oncology Group Study (ADVL0912)","volume":"27","author":"Foster","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.022_bib29","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"issue":"12 Pt 1","key":"10.1016\/j.hoc.2026.05.022_bib30","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.022_bib31","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamaoncol.2015.5689","article-title":"Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study","volume":"2","author":"Harris","year":"2016","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.022_bib33","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-17-0381","article-title":"Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial","volume":"23","author":"Harttrampf","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.022_bib34","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOP.0000000000000570","article-title":"Precision medicine in pediatric oncology","volume":"30","author":"Forrest","year":"2018","journal-title":"Curr Opin Pediatr"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.022_bib36","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.21.02838","article-title":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children\u2019s Oncology Group Pediatric MATCH Trial","volume":"40","author":"Parsons","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw274","article-title":"Target and Agent Prioritization for the Children\u2019s Oncology Group-National Cancer Institute Pediatric MATCH Trial","volume":"109","author":"Allen","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2026.05.022_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","volume":"150","author":"Pasqualini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/08880018.2014.947009","article-title":"Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis","volume":"31","author":"Mullassery","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00383-012-3109-3","article-title":"Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?","volume":"28","author":"Zwaveling","year":"2012","journal-title":"Pediatr Surg Int"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/2159-8290.CD-21-1094","article-title":"A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era","volume":"12","author":"Pfister","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-19-0692","article-title":"Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies","volume":"8","author":"Casey","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hoc.2026.05.022_bib43","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14728214.2017.1294159","article-title":"Advances in emerging drugs for the treatment of neuroblastoma","volume":"22","author":"Berlanga","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"issue":"24","key":"10.1016\/j.hoc.2026.05.022_bib46","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","article-title":"Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project","volume":"29","author":"London","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib48","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.022_bib49","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"2012","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib51","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with \u03b2-glucan for high-risk neuroblastoma in second or later remission","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41568-019-0141-9","article-title":"Long path to MYC inhibition approaches clinical trials","volume":"19","author":"Villanueva","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.022_bib53","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.1998.16.6.2007","article-title":"Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study","volume":"16","author":"Katzenstein","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib54","doi-asserted-by":"crossref","first-page":"e97285","DOI":"10.1371\/journal.pone.0097285","article-title":"Targeting of the MYCN protein with small molecule c-MYC inhibitors","volume":"9","author":"M\u00fcller","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2026.05.022_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12935-019-1072-y","article-title":"Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.022_bib56","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov"},{"issue":"7213","key":"10.1016\/j.hoc.2026.05.022_bib58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nature07260","article-title":"Modelling Myc inhibition as a cancer therapy","volume":"455","author":"Soucek","year":"2008","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.022_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00248-19","article-title":"Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene","volume":"39","author":"Demma","year":"2019","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2022-0067","article-title":"Direct MYC Inhibitor Passes First Clinical Test","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.022_bib61","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.30440","article-title":"A phase I\/Ib trial targeting the Pi3k\/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma","volume":"140","author":"Kushner","year":"2017","journal-title":"Int J Cancer"},{"issue":"29","key":"10.1016\/j.hoc.2026.05.022_bib63","doi-asserted-by":"crossref","first-page":"46187","DOI":"10.18632\/oncotarget.10070","article-title":"Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with \u03b2-catenin-dependent and \u03b2-catenin-independent signaling pathways","volume":"7","author":"Zins","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.022_bib64","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/onc.2009.80","article-title":"The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt\/beta-catenin pathway","volume":"28","author":"Flahaut","year":"2009","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.022_bib65","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1158\/0008-5472.CAN-18-1045","article-title":"RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma","volume":"78","author":"Eleveld","year":"2018","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.022_bib66","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/jnci\/djp355","article-title":"Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53","volume":"101","author":"Van Maerken","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.022_bib67","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.bmcl.2013.08.018","article-title":"Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis","volume":"23","author":"Ramaiah","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.022_bib68","first-page":"5269","article-title":"Absence of p53 gene mutations in primary neuroblastomas","volume":"53","author":"Vogan","year":"1993","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib69","doi-asserted-by":"crossref","first-page":"e1936","DOI":"10.1038\/cddis.2015.302","article-title":"Reactivation of p53 via MDM2 inhibition","volume":"6","author":"Kim","year":"2015","journal-title":"Cell Death Dis"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.022_bib70","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/jnci\/djp376","article-title":"Targeted molecular therapy for neuroblastoma: the ARF\/MDM2\/p53 axis","volume":"101","author":"Kim","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2026.05.022_bib71","doi-asserted-by":"crossref","first-page":"15026","DOI":"10.1038\/cddiscovery.2015.26","article-title":"The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma","volume":"1","author":"Lakoma","year":"2015","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10456-011-9210-8","article-title":"Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma","volume":"14","author":"Patterson","year":"2011","journal-title":"Angiogenesis"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.022_bib73","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children\u2019s Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib74","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-15-1449","article-title":"Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition","volume":"22","author":"Henssen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib75","first-page":"2521","article-title":"Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs","volume":"35","author":"Haug","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.sempedsurg.2016.09.003","article-title":"Wilms tumor: \"State-of-the-art\" update, 2016","volume":"25","author":"Irtan","year":"2016","journal-title":"Semin Pediatr Surg"},{"issue":"27","key":"10.1016\/j.hoc.2026.05.022_bib77","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2015.62.1888","article-title":"Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration","volume":"33","author":"Dome","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib78","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.omto.2021.06.016","article-title":"Systematic review of the immunological landscape of Wilms tumors","volume":"22","author":"Palmisani","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpurol.2020.03.016","article-title":"Relationship of tumour-associated macrophages with poor prognosis in Wilms\u2019 tumour","volume":"16","author":"Tian","year":"2020","journal-title":"J Pediatr Urol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib80","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tranon.2014.05.008","article-title":"Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in Wilms tumors","volume":"7","author":"Maturu","year":"2014","journal-title":"Transl Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.022_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26613","article-title":"Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors","volume":"64","author":"Pinto","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/08880018.2019.1578843","article-title":"Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy","volume":"36","author":"Mochizuki","year":"2019","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib83","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cjp2.152","article-title":"Biomarker recommendation for PD-1\/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells","volume":"6","author":"Silva","year":"2020","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.022_bib85","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2350\/08-10-0544.1","article-title":"Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry","volume":"13","author":"Scursoni","year":"2010","journal-title":"Pediatr Dev Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.022_bib87","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/pbc.25631","article-title":"A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies","volume":"62","author":"Cacciavillano","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.022_bib88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/CJI.0b013e3181826d72","article-title":"Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor","volume":"31","author":"Meany","year":"2008","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00002371-199408000-00006","article-title":"Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children\u2019s Cancer Group study","volume":"16","author":"Seibel","year":"1994","journal-title":"J Immunother Emphas Tumor Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib90","doi-asserted-by":"crossref","first-page":"pkz007","DOI":"10.1093\/jncics\/pkz007","article-title":"Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012","volume":"3","author":"Hubbard","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib91","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib92","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0022-3476(05)80297-5","article-title":"Risk of hepatoblastoma in familial adenomatous polyposis","volume":"119","author":"Giardiello","year":"1991","journal-title":"J Pediatr"},{"issue":"3 Pt 1","key":"10.1016\/j.hoc.2026.05.022_bib93","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0022-3476(98)70008-3","article-title":"Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry","volume":"132","author":"DeBaun","year":"1998","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.29672","article-title":"New insights into diagnosis and therapeutic options for proliferative hepatoblastoma","volume":"68","author":"Hooks","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib96","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","article-title":"Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications","volume":"73","author":"Carrillo-Reixach","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.022_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070926","article-title":"Wnt\/\u03b2-Catenin Signaling in Liver Cancers","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib98","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.28975","article-title":"Targeting \u03b2-catenin in hepatocellular cancers induced by coexpression of mutant \u03b2-catenin and K-Ras in mice","volume":"65","author":"Tao","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.022_bib99","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s10147-013-0625-7","article-title":"Current therapeutic strategies for childhood hepatic tumors: surgical and interventional treatments for hepatoblastoma","volume":"18","author":"Hishiki","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/bjc.2012.539","article-title":"Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts","volume":"108","author":"Eicher","year":"2013","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib101","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s11912-022-01230-2","article-title":"Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy","volume":"24","author":"Wu","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.022_bib102","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-08-2878","article-title":"Activation of phosphatidylinositol-3\u2019-kinase\/AKT signaling is essential in hepatoblastoma survival","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.022_bib103","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.ejca.2011.12.032","article-title":"Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients","volume":"48","author":"Wagner","year":"2012","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.hoc.2026.05.022_bib104","doi-asserted-by":"crossref","first-page":"22665","DOI":"10.18632\/oncotarget.25205","article-title":"Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma","volume":"9","author":"Stafman","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/carcin\/22.3.447","article-title":"Transforming growth factor-beta1-induced Smad signaling, cell-cycle arrest and apoptosis in hepatoma cells","volume":"22","author":"Buenemann","year":"2001","journal-title":"Carcinogenesi"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s100380300008","article-title":"Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK\/STAT inhibitor, in human hepatoblastomas","volume":"48","author":"Nagai","year":"2003","journal-title":"J Hum Genet"},{"issue":"60","key":"10.1016\/j.hoc.2026.05.022_bib107","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.18632\/oncotarget.27237","article-title":"Volasertib preclinical activity in high-risk hepatoblastoma","volume":"10","author":"Kats","year":"2019","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib108","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/hep.31919","article-title":"Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models","volume":"74","author":"Johnston","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib109","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41598-021-82542-4","article-title":"MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma","volume":"11","author":"Woodfield","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib110","doi-asserted-by":"crossref","first-page":"e22620","DOI":"10.4161\/onci.22620","article-title":"Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma","volume":"2","author":"Armeanu-Ebinger","year":"2013","journal-title":"OncoImmunology"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.022_bib111","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/cncr.24465","article-title":"Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005","volume":"115","author":"Ognjanovic","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.2003.06.129","article-title":"Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV","volume":"21","author":"Breneman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib113","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pbc.24532","article-title":"PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children\u2019s oncology group report","volume":"60","author":"Skapek","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"40","key":"10.1016\/j.hoc.2026.05.022_bib114","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1038\/sj.onc.1204599","article-title":"Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma","volume":"20","author":"Barr","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2026.05.022_bib115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jconrel.2016.05.063","article-title":"RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy","volume":"235","author":"Rengaswamy","year":"2016","journal-title":"J Control Release"},{"issue":"557","key":"10.1016\/j.hoc.2026.05.022_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau7632","article-title":"The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma","volume":"11","author":"Bharathy","year":"2018","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejca.2011.09.021","article-title":"Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma","volume":"48","author":"Geoerger","year":"2012","journal-title":"Eur J Cancer"},{"issue":"31","key":"10.1016\/j.hoc.2026.05.022_bib118","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.19.00576","article-title":"Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children\u2019s Oncology Group","volume":"37","author":"Mascarenhas","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib119","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2018.02.011","volume":"94","author":"Sch\u00f6ffski","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib120","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib121","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cncr.31770","article-title":"The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children\u2019s Oncology Group","volume":"125","author":"Malempati","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib122","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.25334","article-title":"Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group","volume":"62","author":"Wagner","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib123","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pbc.25548","article-title":"Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children\u2019s Oncology Group","volume":"62","author":"Kim","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib124","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib125","first-page":"23","article-title":"Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum","volume":"14","author":"Bacci","year":"1988","journal-title":"Ital J Orthop Traumatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib126","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell Rep"},{"issue":"57","key":"10.1016\/j.hoc.2026.05.022_bib127","doi-asserted-by":"crossref","first-page":"96738","DOI":"10.18632\/oncotarget.18236","article-title":"Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma","volume":"8","author":"Nakka","year":"2017","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.hoc.2026.05.022_bib128","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib129","doi-asserted-by":"crossref","first-page":"830546","DOI":"10.3389\/fonc.2022.830546","article-title":"Novel Immunotherapies for Osteosarcoma","volume":"12","author":"Lu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib130","doi-asserted-by":"crossref","first-page":"1747677","DOI":"10.1080\/2162402X.2020.1747677","article-title":"Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions","volume":"9","author":"Wolf-Dennen","year":"2020","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib131","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib132","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.25688","article-title":"Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma","volume":"63","author":"Roth","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib133","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/pbc.25099","article-title":"Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program","volume":"61","author":"Kolb","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2026.05.022_bib134","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","article-title":"Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children\u2019s Oncology Group","volume":"121","author":"Kopp","year":"2019","journal-title":"Eur J Cancer"},{"issue":"Pt 4","key":"10.1016\/j.hoc.2026.05.022_bib135","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1242\/jcs.094029","article-title":"Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells","volume":"125","author":"Beristain","year":"2012","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hoc.2026.05.022_bib137","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.jbo.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.hoc.2026.05.022_bib138","doi-asserted-by":"crossref","first-page":"100362","DOI":"10.1016\/j.jbo.2021.100362","article-title":"Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis","volume":"28","author":"M\u00fadry","year":"2021","journal-title":"J Bone Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.022_bib139","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41401-019-0262-4","article-title":"Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells","volume":"40","author":"Shao","year":"2019","journal-title":"Acta Pharmacol Sin"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.022_bib140","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2026.05.022_bib141","series-title":"The national academies collection: reports funded by national institutes of health. Addressing the barriers to pediatric drug development: workshop summary","author":"Institute of Medicine Forum on Drug Discovery D, Translation","year":"2008"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib142","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2015.10080","article-title":"Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth","volume":"314","author":"Mody","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2026.05.022_bib143","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","article-title":"Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study","volume":"65","author":"Worst","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.022_bib144","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2010.07.024","article-title":"Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas","volume":"81","author":"Yoon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.022_bib145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40264-014-0139-x","article-title":"Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients","volume":"37","author":"Shah","year":"2014","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.022_bib146","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/TP.0b013e318192dd56","article-title":"A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients","volume":"87","author":"Tiong","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.hoc.2026.05.022_bib147","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"Xiao","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.022_bib148","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib149","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.022_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112774","article-title":"Blood-Derived Liquid Biopsies Using Foundation One(\u00ae) Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience","volume":"14","author":"Cahn","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.022_bib151","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.022_bib152","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.022_bib153","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.022_bib154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882600064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882600064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:19Z","timestamp":1788390139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882600064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":154,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S088985882600064X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.022","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Oncology in Pediatric Cancer Surgery","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}